Article in Islets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Sawash M MohammedCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Robert N BoneCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Jacqueline Del Carmen AquinoCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Raghavendra G MirmiraKovler Diabetes Center and the Department of Medicine, The University of Chicago, Chicago, IL, USA.
Carmella Evans-MolinaCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Heba M IsmailCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-0102-0030
Funding
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Pilot and Feasibility ProgramP30DK020595 · NIDDK · UNIVERSITY OF CHICAGO · PI Matthew J Brady · 2013 to 2026
$20.9M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Transcriptional Mechanisms Governing Beta Cell DifferentiationR01DK060581 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Raghavendra G Mirmira · 2002 to 2026
$8.5M
The Integrated Stress Response in Human Islets During Early T1DU01DK127786 · NIDDK · UNIVERSITY OF CHICAGO · PI EVANS-MOLINA, CARMELLA, MIRMIRA, RAGHAVENDRA G · 2020 to 2025
$7.1M
Early Pathogenesis of Cystic Fibrosis Related DiabetesRC2DK124207 · NIDDK · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F, NORRIS, ANDREW W · 2021 to 2023
$4.5M
Indiana University clinical Center for acute pancreatitis and diabetes clinical research networkU01DK127382 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina, Evan L Fogel · 2020 to 2026
$2.4M
Control of beta cell function and survival by RYR2-mediated calcium signalsR01DK127236 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA · 2021 to 2025
$2.2M
NATIONAL FERRET RESOURCE AND RESEARCH CENTER ON LUNG DISEASE75N92019C00010 · NHLBI · UNIVERSITY OF IOWA · PI BOYLE, JESSICA · 2023 to 2023
$1.1M
The Gut Microbiome in Lean and Obese Youth with Type 1 Diabetes and Novel Mechanism of Action of MetforminK23DK129799 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI ISMAIL, HEBATULLAH · 2022 to 2025
backgroundKnockout (KO) ferrets with the cystic fibrosis transmembrane conductance regulator (CFTR) exhibit distinct phases of dysglycemia and pancreatic remodeling prior to cystic fibrosis-related diabetes (CFRD) development. Following normoglycemia during the first month of life (Phase l), hyperglycemia occurs during the subsequent 2 months (Phase Il) with decreased islet mass, followed by a period of near normoglycemia (Phase Ill) in which the islets regenerate. We aimed to characterize islet hormone expression patterns across these Phases.
methodsImmunofluorescence staining per islet area was performed to characterize islet hormone expression patterns in age matched CFTR KO and wild type (WT) ferrets, focusing on the first three phases.
resultsIn Phase I, insulin staining intensity was higher in CF (
conclusionCF ferret islets revealed significant immunofluorescent staining changes compared to WT during various phases of disease, providing insights into CRFD pathophysiology.
Indexed as
Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDisease Models, AnimalFerretsIslets of LangerhansRegenerationAnimalsDiabetes MellitusFemaleFluorescent Antibody TechniqueGlucagonInsulinMaleProinsulinCystic Fibrosis Transmembrane Conductance RegulatorGlucagonInsulinProinsulinAlpha and beta cellscystic fibrosis-related diabetesferret modelglucagon stainingglucagon-to-insulin ratioglycemic phasesImmunostaininginsulin stainingproinsulin stainingproinsulin-to-insulin colocalizationproinsulin-to-insulin ratio
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Changes in immunofluorescence staining during islet regeneration in a cystic fibrosis-related diabetes (CFRD) ferret model. · full record | OpenQuestion